{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:01:48Z","timestamp":1774958508988,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HUCS-EVO","award":["TYH2017118"],"award-info":[{"award-number":["TYH2017118"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The aim of this study was to assess the prevalence, incidence rate (IR), predisposing factors, survival rate, and diagnostic delay of progressive multifocal leukoencephalopathy (PML) across medical specialties. Another objective was to survey how PML diagnosis was made in the studied cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a cross-sectional retrospective observational study of PML cases across different medical specialties during 2004\u20132016 in the Finnish Capital Region and Southern Finland. Data were obtained from clinical records, clinical microbiology, pathology and radiology department records, and human immunodeficiency virus (HIV) quality register medical records.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 31 patients were diagnosed with PML. The prevalence of PML was 1.56 per 100 000 people and the IR was 0.12 per 100 000 individuals per year during 2004\u20132016. Hematologic malignancies (n = 19) and HIV\/acquired immune deficiency syndrome (n = 5) were the most common underlying diseases, and all patients who had malignant diseases had received cancer treatment. Before PML diagnosis, 21 (67.7%) patients were treated with chemotherapy, 14 (45.2%) patients with rituximab, and 1 patient (3.2%) with natalizumab. Two patients (6.5%) had no obvious immunocompromising disease or treatment. Neither gender, age, first symptoms, previous medication, nor underlying disease influenced the survival of PML patients significantly. The 5-year survival rate was poor, at less than 10%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The majority of PML patients in our study had a predisposing disease or had immunosuppressive or monoclonal antibody therapy. In the future, broader use of immunosuppressive and immunomodulatory medications may increase incidence of PML among patients with diseases unassociated with PML. Safety screening protocols for John Cunningham virus and PML are important to prevent new PML cases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofz024","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T21:40:18Z","timestamp":1548366018000},"source":"Crossref","is-referenced-by-count":25,"title":["The Incidence and Predisposing Factors of John Cunningham Virus-Induced Progressive Multifocal Leukoencephalopathy in Southern Finland: A Population-Based Study"],"prefix":"10.1093","volume":"6","author":[{"given":"Marge","family":"Kartau","sequence":"first","affiliation":[{"name":"Clinical Neurosciences, Neurology, Helsinki University Hospital and Helsinki University, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auli","family":"Verkkoniemi-Ahola","sequence":"additional","affiliation":[{"name":"Clinical Neurosciences, Neurology, Helsinki University Hospital and Helsinki University, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Paetau","sequence":"additional","affiliation":[{"name":"Department of Pathology (Neuropathology), Helsinki University Hospital Laboratory (HUSLAB), Helsinki University Hospital and Helsinki University, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarit","family":"Palom\u00e4ki","sequence":"additional","affiliation":[{"name":"Neuroradiology, HUS Medical Imaging Center, Helsinki University Hospital and Helsinki University, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Janes","sequence":"additional","affiliation":[{"name":"Department of Oncology, Helsinki University Hospital and Helsinki University, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matti","family":"Ristola","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital and Helsinki University, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maija","family":"Lappalainen","sequence":"additional","affiliation":[{"name":"Laboratory Services (HUSLAB), Department of Virology and Immunology, Helsinki University Hospital and Helsinki University, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veli-Jukka","family":"Anttila","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital and Helsinki University, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"2020081003482864800_CIT0001","doi-asserted-by":"crossref","first-page":"13490","DOI":"10.1128\/JVI.02252-13","article-title":"5-HT2 receptors facilitate JC polyomavirus entry","volume":"87","author":"Assetta","year":"2013","journal-title":"J Virol"},{"key":"2020081003482864800_CIT0002","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-pathol-020712-164018","article-title":"Progressive multifocal leukoencephalopathy: why gray and white matter","volume":"8","author":"Gheuens","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"2020081003482864800_CIT0003","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1212\/01.wnl.0000233918.21986.9c","article-title":"Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population","volume":"67","author":"Eng","year":"2006","journal-title":"Neurology"},{"key":"2020081003482864800_CIT0004","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1212\/WNL.0000000000004926","article-title":"The national incidence of PML in Sweden, 1988\u20132013","volume":"90","author":"Iacobaeus","year":"2018","journal-title":"Neurology"},{"key":"2020081003482864800_CIT0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jbspin.2011.11.002","article-title":"Progressive multifocal leukoencephalopathy in autoimmune diseases","volume":"79","author":"Palazzo","year":"2012","journal-title":"Joint Bone Spine"},{"key":"2020081003482864800_CIT0006","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2042098612453849","article-title":"Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps","volume":"3","author":"Zaheer","year":"2012","journal-title":"Ther Adv Drug Saf"},{"key":"2020081003482864800_CIT0007","doi-asserted-by":"crossref","first-page":"1073274817729901","DOI":"10.1177\/1073274817729901","article-title":"progressive multifocal leukoencephalopathy and monoclonal antibodies: a review","volume":"24","author":"Bohra","year":"2017","journal-title":"Cancer Control"},{"key":"2020081003482864800_CIT0008","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cpt.604","article-title":"Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators\u2019 perspective","volume":"102","author":"Anton","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2020081003482864800_CIT0009","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fimmu.2017.00577","article-title":"Immune reconstitution inflammatory syndrome unmasking or worsening AIDS-related progressive multifocal leukoencephalopathy: a literature review","volume":"8","author":"Fournier","year":"2017","journal-title":"Front Immunol"},{"key":"2020081003482864800_CIT0010","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"2020081003482864800_CIT0011","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"2020081003482864800_CIT0012","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"2020081003482864800_CIT0013","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"2020081003482864800_CIT0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2015.01.019","article-title":"Expression of BKV and JCV encoded microRNA in human cerebrospinal fluid, plasma and urine","volume":"65","author":"Pietil\u00e4","year":"2015","journal-title":"J Clin Virol"},{"key":"2020081003482864800_CIT0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/B978-0-444-53488-0.00017-1","article-title":"Progressive multifocal leukoencephalopathy","volume":"123","author":"Berger","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"2020081003482864800_CIT0016","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crad.2010.03.001","article-title":"Imaging manifestations of progressive multifocal leukoencephalopathy","volume":"65","author":"Shah","year":"2010","journal-title":"Clin Radiol"},{"key":"2020081003482864800_CIT0017","author":"Hospital District Map","year":"2017"},{"key":"2020081003482864800_CIT0018","volume-title":"Early Diagnosis of PML: Results from the Italian Cohort","author":"Scarpazza","year":"2017"},{"key":"2020081003482864800_CIT0019","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s13311-017-0570-7","article-title":"Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies","volume":"14","author":"Williamson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"2020081003482864800_CIT0020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1148\/radiology.173.2.2798883","article-title":"Progressive multifocal leukoencephalopathy in patients with AIDS: appearance on MR images","volume":"173","author":"Mark","year":"1989","journal-title":"Radiology"},{"key":"2020081003482864800_CIT0021","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1212\/WNL.36.4.499","article-title":"Progressive multifocal leukoencephalopathy: JC virus detection by in situ hybridization compared with immunohistochemistry","volume":"36","author":"Aksamit","year":"1986","journal-title":"Neurology"},{"key":"2020081003482864800_CIT0022","first-page":"25","article-title":"Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life","volume":"5","author":"Planas","year":"2014","journal-title":"Patient Relat Outcome Meas"},{"key":"2020081003482864800_CIT0023","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/acn3.301","article-title":"Diagnostic delay in progressive multifocal leukoencephalopathy","volume":"3","author":"Miskin","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"2020081003482864800_CIT0024","doi-asserted-by":"crossref","first-page":"e12879","DOI":"10.1111\/tid.12879","article-title":"Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation: case report and review of the literature","volume":"20","author":"Yuan","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2020081003482864800_CIT0025","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/598335","article-title":"Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study","volume":"48","author":"Khanna","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020081003482864800_CIT0026","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1086\/595299","article-title":"Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study","volume":"199","author":"Engsig","year":"2009","journal-title":"J Infect Dis"},{"key":"2020081003482864800_CIT0027","first-page":"23","article-title":"Progressive multifocal leukoencephalopathy","volume":"137","author":"Alstadhaug","year":"2017","journal-title":"Tidsskr Nor Legeforen"},{"key":"2020081003482864800_CIT0028","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","article-title":"Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Vermersch","year":"2011","journal-title":"Neurology"},{"key":"2020081003482864800_CIT0029","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","article-title":"Classifying PML risk with disease modifying therapies","volume":"12","author":"Berger","year":"2017","journal-title":"Mult Scler Relat Disord"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/2\/ofz024\/33576142\/ofz024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/2\/ofz024\/33576142\/ofz024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:05:10Z","timestamp":1597046710000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz024\/5299783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz024","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2,1]]},"article-number":"ofz024"}}